|
Palo Alto, CA, December 3, 2003 — Telik, Inc. (Nasdaq:
TELK) announced that it will present positive interim results from
the Phase 1-2a clinical trial of TELINTRA™ (TLK199) in patients
with myelodysplastic syndrome at the American Society of Hematology
annual meeting.
The presentation, “Hematologic Improvement Following Treatment
with TLK199 (a Novel Glutathione Analog Inhibitor of GST P1-1) in
Myelodysplastic Syndrome: Interim Results of a Phase 1-2a Study”,will
take place on Saturday, December 6, 2003 in San Diego, California.
About Telik, Inc.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TELCYTA™. Telik's product candidates were discovered using
its proprietary technology, TRAP, which enables the rapid and efficient
discovery of small molecule drug candidates. Additional information
is available at www.telik.com.
You should not rely on forward-looking statements contained in
this press release, including statements regarding our ability to
successfully develop TELINTRA™ for MDS or any other condition,
its tolerability, potential efficacy or market potential. Telik
can give no assurance with regard to these statements. None of our
products have been determined to be safe or effective in humans
or been approved for marketing. Substantial additional testing will
be necessary prior to seeking marketing approval. There can be no
assurance that such trials will accrue sufficient patients, be conducted
with sufficient quality, in a timely manner, have a successful outcome,
or that regulatory approval will be obtained. In addition, we are
reliant on external manufacturing, and any interruption or delay
in drug supply could adversely affect the development program. More
detailed information regarding factors that may cause actual results
to differ materially from the results expressed or implied by statements
in this press release may be found in Telik's periodic filings with
the Securities and Exchange Commission. Telik assumes no obligation
to update any information in this press release.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
